Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
bNAbs, N-803, and Vaccines for HIV Remission
NCT05769569Phase 1Withdrawn
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Start
- Sep 2023
- Primary completion
- Jul 2025
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of VRC07-523LS, PGDM1400LS, nogapendekin alfa inbakicept, Ad26.Mos4.HIV, MVA-mBN32 and 1 more in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine. Primary endpoints: Safety of VRC07-523LS, PGDM1400LS and N-803 in combination with vaccines and Time to sustained viral rebound to >=1000 copies/mL. Planned start Sep 2023; status: withdrawn.
02
Drugs
VRC07-523LSPGDM1400LSnogapendekin alfa inbakiceptAd26.Mos4.HIVMVA-mBN32
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05769569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05769569.